Pipeline
Multi-Indication Oncology
Pipeline. One Platform.
Advancing a multi-indication oncology pipeline built on the proprietary AVIDIO™ virus-like vesicle platform — originally discovered at Yale School of Medicine. Lead asset CARG-2020 is in IND-enabling development for recurrent ovarian cancer, with additional indications in preclinical development.
3
Indications
1
AVIDIO™ Platform
Same Construct
Across all indications
$92.1B
Total addressable market
Current Programs
AVIDIO™ Multi-Indication Platform.
Program
Indication
Stage
Market
CARG-2020
Recurrent Ovarian Cancer
IND-Enabling
$9.7B
CARG-2020
Triple-Negative Breast Cancer
Preclinical
$70.5B
CARG-2020
Melanoma
Preclinical
$11.9B
$9.7B
Lead indication
(ovarian)
$70.5B
Triple-neg.
breast cancer
$11.9B
Melanoma
$92.1B
Total addressable
market
Lead Indication
Recurrent Ovarian Cancer.
CARG-2020's first clinical indication — a population with limited approved options and among the highest unmet needs in oncology.
~22K
U.S. Diagnoses Per Year
New ovarian cancer diagnoses annually in the United States.
~70%
Recurrence Rate
Patients experience disease recurrence after initial treatment.
$9.7B
2030 Market Size
Projected recurrent ovarian cancer treatment market by 2030.
Phase I/Ib Target
Why Ovarian Cancer First
- Capital-efficient PoC: Intraperitoneal delivery enables a focused Phase I/Ib trial in a small patient population.
- Clear clinical path: High unmet need accelerates enrollment and supports priority regulatory review.
- Regulatory advantage: Potential Orphan Drug and Breakthrough Therapy designations.
- Beachhead strategy: Prove efficacy here, then expand the platform across additional tumor types.
Expansion Programs
Preclinical Pipeline.
The same CARG-2020 construct, delivered via the same AVIDIO™ platform, has demonstrated preclinical activity in three additional solid tumor indications — each representing an independent licensing opportunity.
Preclinical
$70.5B
Triple-Negative Breast Cancer
Breast cancer subtype with historically limited treatment options and significant unmet need. Same AVIDIO-delivered construct as ovarian program — no modification required.
Preclinical
$11.9B
Melanoma
Cross-tumor immune memory confirmed in preclinical models. Opportunity in checkpoint-resistant disease where standard immunotherapy fails.
Platform Advantage
Why a Multi-Indication Pipeline is Possible.
Platform-driven development: every new indication leverages the same AVIDIO™ manufacturing process and composition-of-matter patent — each is an independent licensing opportunity.
Investor Opportunity.
Viridion is raising a $20M Series A to advance CARG-2020 into Phase I/Ib trials.
Direct inquiries: balmassian@viridiontherapeutics.com
— Dr. Bijan Almassian, CEO & Founder
— Dr. Bijan Almassian, CEO & Founder